Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy (AYU-STEP)

17. november 2026 opdateret af: European Institute of Oncology

Effect of AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy: Prospective Pilot Study

Chemotherapy-induced peripheral neuropathy (CIPN) affects approximately 40% of patients treated with taxanes. These agents may cause burning pain, paresthesia, numbness, and loss of proprioceptive sensitivity, which can reduce well-being and impair quality of life.In this context, implementing non-pharmacological interventions, such as foot treatment/manipulation proposed in this project, represents a promising area to explore complementary therapies with minimal toxicity and low cost for symptom management.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

20

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Milan, Italien, 20141
        • Rekruttering
        • European Institute of Oncology
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 anni
  • Diagnosis of carcinoma with ongoing treatment or treatment completed within the previous 6 months with taxanes (paclitaxel/docetaxel).
  • Grade 1-2 sensory-motor peripheral neuropathy (NCI-CTCAE v5).
  • Able to walk independently.
  • Written informed consent.

Exclusion Criteria:

  • Pre-existing diabetic neuropathy
  • Foot ulcers or infections
  • Central neurological disorders
  • Concomitant specific treatment for CINP including other complementary medicine. Occasional over the counter drugs such as NSIDs or pain killer are allowed. Any other clinical condition that, at the discretion of the physician or practitioner, may contraindicate participation in the study procedures.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment arm

Manual manipulation of the feet

The treatment consists of manual manipulation of the feet using Mahanarayan oil. Each session lasts approximately 30-40 minutes and is performed with the patient in a supine position, including massage of the foot and lower leg.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of patients that completed the treatment
Tidsramme: From enrollment to the follow-up contact at 10 weeks

Adherence to treatment will be measured as the number of subjects that completed all study treatment sessions on the total number of subjects enrolled.

From enrollment to the follow-up contact at 10 weeks
Incidence of local adverse events related to the use of medicated oils during treatement sessions or manual therapy.
Tidsramme: From enrollment to the follow-up contact at 10 weeks

Incidence will be calculated as the number of local adverse events related to the use of medicated oils during treatement sessions or manual therapy on the total number of treatment sessions administered.

From enrollment to the follow-up contact at 10 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from baseline in the score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale (QLQ-CIPN20) at 10 weeks.
Tidsramme: From enrollment to the follow-up contact at 10 weeks

Impact of treatment on Chemotherapy-induced peripheral neuropathy (CIPN) will be assessed using the QLQ-CIPN20 questionnaire.

The QLQ-CIPN20 questionnaire will be administered four times: before the first treatment, at mid-treatment, at the end of treatment, and at follow-up.

Higher the resulting score mean higher the CIPN affect the patient. Impact of treatment will be defined by the comparison of initial scoring and post treatment scoring.

From enrollment to the follow-up contact at 10 weeks
Change from baseline in the score of The McGill Pain Questionnaire (P.R.I.) at 10 weeks.
Tidsramme: From enrollment to the follow-up contact at 10 weeks

The McGill Pain Questionnaire (P.R.I.) will be administered before the first treatment, at the end of the treatment, and at follow-up.

Higher the resulting score mean higher the paint felt by the patient. Impact of treatment on the reduction of the pain will be defined by the comparison of initial scoring and post treatment scoring.

From enrollment to the follow-up contact at 10 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. november 2026

Primær færdiggørelse (Anslået)

1. december 2030

Studieafslutning (Anslået)

1. januar 2031

Datoer for studieregistrering

Først indsendt

6. oktober 2026

Først indsendt, der opfyldte QC-kriterier

13. oktober 2026

Først opslået (Faktiske)

20. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • UID 5323
  • L2-657 (Anden identifikator: Comitato Etico Lombardia 2)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .